TSH anti-receptor antibodies in Graves' disease.

Authors

  • M R Sérgio Laboratório Endocrinologia, Serviço Patologia Clínica, Unidade Endocrinologia do Hospital Curry Cabral, Lisboa.
  • C Godinho
  • L Guerra
  • A Agapito
  • F Fonseca
  • C Costa

DOI:

https://doi.org/10.20344/amp.2603

Abstract

The purpose of this study was to evaluate the sensitivity, specificity and predictive value of thyrotropin receptor antibody (TRAb) in the diagnosis of Graves disease. TRAb was tested by an isotopic receptor assay-TRAK Henning-in 80 newly diagnosed, untreated Graves disease patients (group I), 63 with other thyroid diseases (group II) and 60 controls (group III). In group I, 11 patients were TRAb negative and 7 were considered in the gray area (TRAb between 9 and 14 U/L). In group II, only 2 patients had TRAb 9 U/l and all controls were TRAb negative. For statistical analysis patients with TRAb in gray area were excluded. Sensitivity and specificity for this assay were 84.5 and 100% respectively. Predictive value of 100% affords certainty that a hyperthyroid patient with a positive TRAb has Graves disease, not sequining a scintigram.

Downloads

Download data is not yet available.

Downloads

How to Cite

1.
Sérgio MR, Godinho C, Guerra L, Agapito A, Fonseca F, Costa C. TSH anti-receptor antibodies in Graves’ disease. Acta Med Port [Internet]. 1996 Sep. 30 [cited 2024 Dec. 23];9(7-9):229-31. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/2603

Issue

Vol. 9 No. 7-9 (1996): Julho-Setembro

Section

Arquivo Histórico

License

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

Crossref
Scopus
Google Scholar
Europe PMC